Adar R, Papa MC, Halperin Zet al.Cellular sensitivity to collagen and thromboangiitis obliterans. N Engl J Med1983; 308: 1113-1116.
3.
Kobayashi M, Ito M, Nakagawa A, Nishikimi N, Nimura Y.Immunohistochemical analysis of arterial wall cellular infiltration in Buerger’s disease (endarteritis obliterans). J Vasc Surg1999; 29: 451-458.
4.
Eichhorn J, Sima D, Lindschau Cet al.Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci1998; 31: 17-23.
5.
Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR.The changing clinical spectrum of thromboangiitis obliterans. Circulation1990; 82 (suppl): IV-3-IV-8.
Harris EN.Special Report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) Group. Am J Clin Pathol1990; 94: 476-484.
Wilson WA, Gharavi AE, Koike Tet al.International Consensus Statement On Preliminary classification Criteria for Definite Antiphospholipid Syndrome. Report of an international workshop. Arthritis Rheum1999; 42: 1309-1311.
Brandt JT, Barna LK, Triplett DA.Laboratory Identification of lupus anticoagulants: results of the second international workshop for identification of lupus anticoagulants. Thromb Haemost1995; 74: 1185-1190.
12.
Olin JW, Childs MB, Bartholomew JR, Calabrese LH, Young JR.Anticardiolipin antibodies and homocysteine levels in patients with thromboangiitis obliterans. Arthritis Rheum1996; 39: S-47-S-47.